Folate Receptor α (FRα): A Prime Target for Cancer Therapy and ANT BIO PTE. LTD.'s Antibody Solutions

1. Concept: Folate Receptor α (FRα) and Its Role in Cancer Biology

Folate is an essential nutrient for DNA synthesis, repair, and cellular proliferation—processes that are abnormally heightened in cancer cells. The folate one-carbon metabolic pathway, critical for sustaining tumor growth and survival, has emerged as a key therapeutic target in oncology. Among the primary folate transporters mediating cellular folate uptake—Reduced Folate Carrier (RFC), Proton-Coupled Folate Transporter (PCFT), and Folate Receptor α (FRα)—only FRα has been validated as a direct target for anticancer drug development.

Folate Receptor α (FRα), also known as FOLR1 or folate-binding protein, is a 38–40 kDa glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein encoded by the FOLR1 gene (comprising 7 exons and 6 introns). It features a high-affinity folate-binding domain and a GPI anchor site that tethers it to the cell membrane. Beyond folate transport, FRα exhibits multifunctional roles in cancer: regulating tumor proliferation, mediating signal transduction (e.g., JAK/STAT3, LYN/PEAK1 pathways), and acting as a nuclear transcription factor following internalization. Its restricted expression in normal tissues and overexpression in multiple solid tumors make it a highly specific and attractive target for cancer diagnosis and therapy.

2. Research Frontiers of FRα-Targeted Cancer Therapies

Contemporary research on FRα focuses on advancing targeted therapeutic strategies and expanding their clinical utility. A key frontier is the development of next-generation antibody-drug conjugates (ADCs) with improved payload potency, linker stability, and tumor penetration to overcome resistance to first-generation FRα-targeted ADCs. Another prominent direction involves optimizing bispecific antibodies and CAR-T cell therapies to enhance tumor specificity and reduce off-target toxicity, particularly in FRα-low expressing tumors. Additionally, combining FRα-targeted therapies with immune checkpoint inhibitors or chemotherapy is being explored to synergistically enhance antitumor efficacy and overcome immunosuppressive tumor microenvironments. Furthermore, research is leveraging FRα for precision imaging and companion diagnostics, enabling patient stratification and real-time monitoring of treatment response.

3. Research Significance of FRα in Cancer Treatment

FRα’s unique expression pattern and functional roles confer profound significance for cancer research and clinical practice:

• Tumor-specific targeting: FRα is overexpressed in 76–89% of epithelial ovarian cancers, 14–74% of non-small cell lung cancers, 35–68% of triple-negative breast cancers, and 72–100% of mesotheliomas, while being minimally expressed in normal tissues. This specificity minimizes on-target/off-tumor toxicity.
• Broad therapeutic applicability: FRα-targeted strategies span imaging, monoclonal antibodies, ADCs, CAR-T cells, and small molecules, catering to diverse cancer types and treatment stages.
• Addressing unmet needs: FRα-targeted therapies offer new options for patients with refractory or recurrent cancers (e.g., platinum-resistant ovarian cancer) who have limited treatment alternatives.
• Personalized medicine advancement: FRα expression testing enables patient stratification, ensuring that targeted therapies are administered to those most likely to benefit.
• Translational potential: Preclinical and clinical success of FRα-targeted agents (e.g., Elahere) validates the target’s utility, driving the development of novel combination therapies and diagnostic tools.

4. Relevant Mechanisms, Research Methods and Product Applications

4.1 Core Mechanisms of FRα in Cancer Progression

• Folate transport: FRα mediates folate uptake via receptor-mediated endocytosis, supplying cancer cells with the folate required for enhanced DNA synthesis and proliferation.
• Signal transduction: FRα interacts with co-receptors (e.g., GP130) and kinases (e.g., LYN) to activate oncogenic pathways (JAK/STAT3, PEAK1), promoting tumor invasion, metastasis, and survival.
• Nuclear function: Internalized FRα translocates to the nucleus, acting as a transcription factor to regulate genes involved in cell cycle progression and metabolic reprogramming.

4.2 FRα-Targeted Therapeutic Strategies

• Imaging agents: Folate-conjugated probes (e.g., Folate-FITC/EC17) enable tumor-specific fluorescence or radionuclide imaging, aiding in surgical resection and metastatic lesion detection.
• Monoclonal antibodies: Farletuzumab exerts antitumor effects via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and autophagy induction, with clinical activity in FRα-positive cancers.
• Antibody-drug conjugates (ADCs): Elahere (mirvetuximab soravtansine), a US FDA-approved ADC (March 2024), links an anti-FRα antibody to the microtubule inhibitor DM4, demonstrating efficacy in ovarian and non-small cell lung cancer.
• CAR-T cells: FRα-specific CAR-T cells (incorporating MOv19 scFv and 4-1BB co-stimulatory domain) induce tumor regression in preclinical models and are undergoing Phase I clinical trials.

4.3 Product Applications of ANT BIO PTE. LTD.

ANT BIO PTE. LTD. delivers high-performance antibody solutions for FRα research and clinical translation through its Starter sub-brand—specializing in recombinant antibodies. All products are developed using advanced recombinant rabbit monoclonal antibody platforms, validated for specificity, sensitivity, and stability, and comply with EU 98/79/EC, ISO9001, and ISO13485 certifications. Key offerings include:

• Human Folate Receptor α Recombinant Rabbit mAb (S0B2275, SDT-719-20-2): Exhibits exceptional specificity for human FRα, with minimal cross-reactivity to other folate receptor isoforms. It enables accurate detection of FRα expression in tissue samples and cell lines via immunohistochemistry (IHC), Western blot, and flow cytometry.
• Application versatility: This antibody supports FRα expression profiling (critical for patient stratification), target validation in preclinical studies, and development of companion diagnostics for FRα-targeted therapies. Its high sensitivity ensures reliable detection even in low-expression tumors.

This product provides global partners with high-quality raw materials for FRα research, diagnostic kit development, and therapeutic drug discovery, accelerating advancements in FRα-targeted cancer care.

5. Brand Mission of ANT BIO PTE. LTD.

ANT BIO PTE. LTD. is dedicated to empowering global life science research and clinical practice through high-quality, innovative reagents and professional services. As a leading provider of life science solutions, the company offers a comprehensive portfolio including antibodies, recombinant proteins, ELISA kits, and general laboratory reagents, with three specialized sub-brands: Absin (general reagents and kits), Starter (antibodies), and UA (recombinant proteins). Leveraging advanced R&D platforms—including recombinant antibody development (rabbit/mouse monoclonal), protein expression systems (E.coli, CHO, HEK293, Insect Cells), One-Step ELISA, and PTM Pan-Modification Antibody platforms—ANT BIO PTE. LTD. adheres to the principles of "precision, reliability, and customer-centricity." The company strives to deliver cost-effective products and tailored support to researchers, clinicians, and biopharmaceutical partners, accelerating the translation of scientific discoveries into improved patient care and advancing the global fight against cancer.

6. Related Product List

7. AI Disclaimer

This article is AI-compiled and interpreted based on the original work. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.